

!"# .'().' +),'-./' +0'1&223'4%56'78&'9&%"75.&-2'1-:"7;',&8-:&'2"<&'7%-/"7"5.-2**±**"%1\$2-7".#> 1&223?"

@A"#\$%&'(`)\*+ +,-. -,-""# <sup>mid</sup>/\$D(1\$!2\$%&'()\*+ +,-. -,-""# -/\$34556\$789:\$;<4\$=48';9(405\$30>';?\$ @484\$<'\*<5?\$50#4541\$'(\$#9;<\$A5BC@';3<\$0(1\$)&D8C@';3<\$5'(40\*4\$;80**3F(#\$&#6#E(0E**'>4\$ 759@\$3?;9:4;8'3\$0(05?**676\$**4=98;48\$4G=8466'9(E\$\$

+A'!"#\$0(1\$+BA\$!2\$34556\$@647847\$30(;5?\$841H341\$'(\$)&DFD(1\$A)-JK\$:'34\$

39:=0841\$;9\$LME\$HO(;'7'30;'9(\$97\$;9;05\$3455\$(H:#486\$'(\$;<4\$=48';9(405\$30>';?E\$-0;0\$084\$ 84=8464(;0;'>4\$97\$OP.\$:'34\$=398598;\$'(\$;<844\$'(14=4(14(;\$4G=48':4(;6E\$\$

C='CBBA\$-9(98\$,<':48'6:\$97\$!"#\$0(1\$!2\$34556\$@06\$6'\*('7'30(;5?\$841H341\$789**'**\$**)%82**AFI\$#086/\$ 0(1\$A)-JK\$%841\$6QH084\$#086/\$19(98\$RC,6\$39:=0841\$;9\$LM\$%\*84?\$#086/\$19(98\$RC,6E\$ NH0(;'7'30;'9(\$97\$19(98\$3<':48'6:\$97\$!!"#\$0(1\$!2\$34556\$846=43;'>'45?E\$ CB&BBA\$,455H508';?\$97\$!!"#\$0(1\$!2\$3**45565\$'@3**0(;5?\$841H341\$789:\$A'5**%**2@<';4\$ #086/S\$ )&DFI<sup>-/-</sup> %841\$#086/\$0(1\$A)-JK\$%841\$6QH084\$#086/\$19(98\$RC,6\$39:=0841\$;**9\$1544\$**\$#086/\$ 19(98\$RC,6E\$NH0(;'7'30;'9(\$97\$;9;05\$!"#\$0(1\$!2\$34556E\$LM\$(T**U**\$**\$\***A**\$B**)&DFI<sup>-/-</sup> (TDS\$A)-JK\$ (TOS\$84=8464(;'(\*\$0\$:'(':H:\$97\$79H8\$'(14=4(14(;\$4G=48':4(;6**H5**\$DBBA\$C'\*('7'30(;5?\$\*840;48\$ 19(98P148'>41\$!!"#\$0(1\$!2\$34556\$'(\$0(\$)&DBH3'='4(;\$%841\$6QH0846/\$39:=0841\$;9\$0\$LM\$ 843'='4(;\$%\*84?\$19;6/E\$NH0(;'7'30;'9(\$97\$19(98P148'>41\$34556\$97\$!!"#\$0(1\$!2\$34556\$\$846=43;'>45?E\$

DB=DBB32A\*('7'30(;5?\$\*840;48\$;9;05\$!2\$34556\$'(\$0(\$)8824Bl='4(;\$%841\$6QH0841/\$

39:=0841\$;9\$0\$LM\$843'='4(;\$%\*84?\$19;6/E\$NH0(;'7'30;'9(\$97\$;9;05\$34556\$%19(98V<96;/\$97\$!"#\$0(1\$ !2\$\$846=43;'>45?E\$LM\$843'='4(;\$(T.\$\$)&**B#3**'='4(;\$(T"WS\$84=8464(;'(\*\$79H8\$

'(14=4(14(;\$ 4G=48':4(;6E\$\$

 $E>EBA'!08\$*80=<\$39:=08'(*\$3'83H50;'(*\$!\$34556\$0(1\$M\&,6\$34556\$0;\$6;401?\$6;0;4\$%\$9\$5;4\$\%9086/\$8439(6;';H;'9(\$H=9(\$;80(6=50(;0;'9(\$97\$LM\$RC,6\$\%=0;;48(\$#)48357H508';?\$97\$!"#$0(1\$!2$'($LM\$98$)&DFf':'34\$084\$39:=0841$;9$LM$0(1$)&DF't:'34\$8439(6;';H;41$@';<$LM$RC,6E$$ -'77484(346$($!P-/$@484$0(05?X41$@';<$;@9P;0'541$C;$H46;(*$$5$E].Y$ ZZS$[\$E]].Y$ZZZS$ [\]E]]].E$-'77484(346$ '($^P^_/$@484$0(05?X41$@';<$9(4P@0?$`aKb`Y$!"#$=T]E]"]D$0(1$!2$'=T]E]"2U$0(1$H((4;;$:H5;'P=080:4;48$;46;Y$$5$E].Y$ ZZS$[\$E]].Y$ZZZS$ [\]E]].E$$ 



!"# .'(0.'CDFG'H'1&223'".'9&%"98&%-2',255/'%&I\$"%&LMKN?"

@AH:#486\$97\$c;801';'9(05d\$,-WV\$M\$34556\$'(\$;<4\$=48'=<4805\$#5991\$97\$e\$;9\$"2\$@44B\$951\$LMS\$
A5B2S\$)&DF't 0(1\$A)-JK\$:'34E\$LM\$%\*84?/S\$A5B2@<';4/S\$)&DF%841/\$0(1\$A5B2
f)&DF1-'-\$19H#54\$B(93B9H;\$%A)-JKY\$841f@<';4/E\$-0;0\$789:\$;<4\$60:4\$:'34\$06\$'(\$A'\*H84\$2E\$
+A\$.]]\$LMS\$A5B2\$)&DF\*198\$A)-JK\$RC,6\$@484\$;80(6=50(;41\$'(;9\$6H#54;<055?\$'8801'0;41\$
75H984634(;\$LM\$843'='4(;6\$%:M:g\$98\$h!,PgA[/\$0(1\$19(98\$3<':48'6:\$97\$=48'=<4805\$#5991\$,-W
V\$M\$34556\$@06\$QH0(;'7'41\$"i\$@44B6\$=96;\$;80(6=50(;0;'9(E\$F439(6;';H;'9(\$97\$M\$34556\$@06\$
6'\*('7'30(;5?\$':=0'841\$H=9(\$;80(6=50(;0;'9(\$97\$)&DF%841\$#086/\$0(1\$A)-JK\$RC,6\$%841f@<';4\$
#086/\$39:=0841\$;9\$LM\$RC,6\$%\*84?\$#086/E\$-0;0\$789:\$;<4\$60:4\$:'34\$06\$'(\$A'\*H84\$WE\$\$
C>CBAE\$.]]\$75H984634(;\$LM\$RC,6\$%h!,PgA[/S\$@484\$;80(6=50(;41\$'(;9\$6H#56;2065;2)\$)
(9(P75H984634(;\$LM\$PRC,6\$%h!,PgA[/S\$@484\$;80(6=50(;41\$'(;9\$6H#56;2065;2)\$)
(9(P75H984634(;\$LM\$PRC,6\$%h!,PgA[/S\$@484\$;80(6=50(;41\$'(;9\$6H#56;2065;2)\$)
@06\$QH0(;'7'41\$"i\$@44B6\$=96;P;80(6=50(;0;\*9(165;98=48'=<4805\$#5991\$,-WV\$M\$34556\$
@06\$QH0(;'7'41\$"i\$@44B6\$=96;P;80(6=50(;0;\*9(165;98=48'=<4805\$#5991\$,-WV\$M\$34556\$
@06\$QH0(;'7'41\$"i\$@44B6\$=96;P;80(6=50(;0;\*9(165;98=48'=<4805\$#5991\$,-WV\$M\$34556\$
@06\$QH0(;'7'41\$"i\$@44B6\$=96;P;80(6=50(;0;\*9(165;98=48'=<4805\$#5991\$,-WV\$M\$34556\$
@06\$QH0(;'7'41\$"i\$@44B6\$=96;P;80(6=50(;0;\*9(165;98=48'=<4805\$#5991\$,-WV\$M\$34556\$
@06\$QH0(;'7'41\$"i\$@44B6\$=96;P;80(6=50(;0;\*9(165;98=48'=<4805\$#5991\$,-WV\$M\$34556\$
@06\$QH0(;'7'41\$"i\$@44B6\$=96;P;80(6=50(;0;\*9(165;98=48'=<4805\$#5991\$,-WV\$M\$34556\$;
A'\*H84\$OE\$\$</pre>

DA\$,455H508';?\$97\$=48'=<4805\$#5991\$,-WV\$M\$34556\$'(\$Ľ**M\$98\$)693F1**\$#086/\$084\$ 39:=0841\$;9\$LM\$0(1\$)&DFf<sup>-</sup>:'34\$8439(6;';H;41\$@';<\$LM\$RC,6\$%=0;;48(\$#086/E\$ -'77484(346\$'(\$`P,\_/\$@484\$0(05?X41\$@';<\$;@9P;0'541\$C;H14(;\$;P;46;\$8450;'>4\$;9\$LM\$:'34S\$0(1\$ 1'77484(346\$'(\$-/\$@484\$0(05?X41\$038966\$055\$79H8\$39(1';'9(6\$#?\$9(4P@0?\$`aKb`\$%=T]E]]WD/\$0(1\$ -H((4;;\$:H5;'P=080:4;48\$;46;E\$ZS\$[\]E].Y\$ZZS\$[\\$\$]E]].Y\$ZZZS\$[\\$\$]E]]].Y\$ZZZS\$[\\$\$]E]]].



## Fig. S3. HSC engraftment was robust, regardless of donor HSC or recipient genotype.

@A\$.]]\$LMS\$A5B\$\$\$)&DF<sup>1</sup>;98\$A)-JK\$RC,6\$@484\$;80(6=50(;41\$'(;9\$6H#54;<055?\$'8801'0;41\$ 75H984634(;\$LM\$843'='4(;6\$%:M:g\$98\$h!,PgA[/\$0(1\$19(98\$3<':48'6:\$97\$=48'=<4805\$#5991\$ g80(H593?;4f+0389=<0\*46\$%g+6/\$34556\$@06\$QH0(;'7'41\$"i\$@44B6\$=96;\$;80(6=50(;0;'9(E\$ F439(6;';H;'9(\$97\$g+6\$@06\$(9;\$6'\*('7'30(;5?\$':=0'841\$H=9(\$;80(6=50(;0;'9(\$97**\$7A5@2**<';4\$#086/S\$ )&DFI<sup>-/-</sup>%841\$#086/S\$98\$A)-JK\$RC,6\$%841f@<';4\$#086/\$39:=0841\$;9\$LM\$RC,6\$%\*84?\$#086/E\$-0;0\$ 789:\$;<4\$60:4\$:'34\$06\$'(\$A'\*H84\$WE**\$**\$

**B,C).** 500 fluorescent WT HSCs (UBC-GFP), were transplanted into sublethally irradiated non-fluorescent WT or IL7R $\alpha$ -/- recipients. Donor contribution to peripheral blood GMs and bone marrow HSCs was quantified 16 weeks post-transplantation. Data from the same mice as in Figure 4. **B)** Donor chimerism of bone marrow HSCs was similar in IL7R $\alpha$ -/- compared to WT recipients. **C)** Donor-derived GM cells/uL of blood was similar in IL7R $\alpha$ -/- compared to WT recipients. Statistics by two-tailed Student t-test. \*\*, P< 0.005.

CA'NH0(;'7'30;'9(\$97\$19(98P148'>41\$)&,26**55** CBA'QH0(;'7'30;'9(\$97\$;9;05\$%<96;V19(98/\$)&,2\$(H:#\$#B650((1\$)&DFI<sup>-/-</sup>\$843'='4(;6E\$-0;0\$789:\$A'\*H84\$OE\$

789:\$A'\*H84\$WE\$\$

+A'-9(98\$,<':48'6:\$0(1\$\$ +BA\$QH0(;'7'30;'9(\$97\$19(98\$)&,26\$'(\$789:\$LM\$RC,**S<sup>4</sup>\$ARCE,2**\$)&DFf<sup>/-</sup> RC,S\$0(1\$A)-JK\$RC,\$:'34E\$-0;0\$

14(9;4\$:054\$:'34\$0(1\$='(B\$3'83546\$14(9;4\$74:054\$:'34E\$\$ @A'NH0(;'7'30;'9(\$97\$)&,26\$'(\$LMS\$<del>A</del>55552)&DF**{**-S\$0(1\$A)-JK\$:'34E\$-0;0\$789:\$A'\*H84\$2E\$

!"# '(Q 'JKC03'".'78&'2\$.#'P&%&"6"2-%2;<del>'</del>44&17&/'".'6-2&'-./'4&6-2&'6"1&?' -0;0\$789:\$7'\*H846\$2S\$W\$0(1\$OS\$@';<\$64G\$146'\*(0;'9(\$97\$403<\$10;0=9'(;E\$!5H4\$6QH0846\$











Α



**Fig. S5. Fetal HSCs had greater mature cell reconstitution capacity compared to adult HSCs.** 250 fetal HSCs and 250 adult HSCs from different fluorescent mice (KuO and UBC- GFP, respectively) were co-transplanted into sublethally irradiated WT recipients and donor contribution to mature cells was quantified >16 weeks post transplantation.

**A)** Donor chimerism of peritoneal B1b and B2 was significantly greater by fetal HSCs compared to adult HSCs.

**B)** Donor chimerism of peripheral blood GMs, B cells and T cells was significantly greater by fetal HSCs compared to adult HSCs. Data from the same mice as in Figure 6. Differences were analyzed with two-tailed Student t test \*, P<0.05; \*\*, P< 0.005; \*\*\*, P<0.005.

Antibody	Source	Identifier	Dilution
B220 - APC Cy7	Biolegend	103224	1:400
CD3- APC	Biolegend	100236	1:200
CD4 - BV605	Biolegend	100451	1:400
CD5 - APC	Biolegend	100625	1:200
CD11b - PB	Biolegend	101223	1:400
CD11b- PECy7	Biolegend	101216	1:400
CD21 - PE Cy7	Ebiosciences	25-0211-82	1:200
CD23 - PB	Biolegend	101616	1:200
CD25 - APC Cy7	Biolegend	102026	1:200
CD45.2 - PB	Biolegend	109820	1:400
CD61-Alexa 647	Biolegend	104314	1:400
CD150 - BV786	Biolegend	115937	1:400
cKit - APC Cy7	Biolegend	105826	1:800
Flk2 - APC	Biolegend	135310	1:100
FoxP3 - PB	Biolegend	126409	1:100
Gr1-Pacific Blue	Biolegend	108430	1:400
lgM - BV605	Biolegend	406523	1:400
KLRG - BV605	Biolegend	138419	1:100
Sca1 - PB	Biolegend	122520	1:400
TCRB - Pe Cy7	Biolegend	109222	1:200
Ter119-PECy5	Biolegend	116210	1:800

## Table S1. Antibodies used in experiments

Antibody	Source	Identifier	Dilution
CD3 - A700	Biolegend	100216	1:100
CD4 - A700	Biolegend	100429	1:400
CD5 - A700	R&D Systems	FAB115N-025	1:400
CD8 - A700	Biolegend	300919	1:200
Ter119 - A700	Biolegend	116220	1:400
B220 - A700	Biolegend	103231	1:400
Gr1 - A700	Biolegend	108421	1:400
CD11b - A700	Biolegend	101222	1:800
CD3 - biotin	Biolegend	100243	1:200
CD4 - biotin	Biolegend	100403	1:200
CD5 - biotin	Biolegend	100603	1:400
CD8 - biotin	Biolegend	100703	1:200
Ter119 - biotin	Biolegend	116203	1:400
Nk1.1 - biotin	Biolegend	108703	1:200
CD19 - biotin	Biolegend	115503	1:400
F4/80 - biotin	Biolegend	123105	1:400
FcεRIα - biotin	Biolegend	101303	1:200
STA - BV786	Biolegend	405249	1:400